Prognostic role of the number of involved extraspinal organs in patients with metastatic spinal cord compression

Dirk Rades, Axel Weber, Johann H. Karstens, Steven E. Schild, Tobias Bartscht

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Objective This study was investigated the prognostic role of the number of involved extraspinal organs in the survival of patients with metastatic spinal cord compression (MSCC). Methods Data of 552 patients treated with 30 Gy in 10 fractions of radiotherapy (RT) alone for MSCC were retrospectively analyzed. In addition to the number of involved extraspinal organs, eight potential prognostic factors were investigated including age, gender, Eastern Cooperative Oncology Group performance score (ECOG-PS), primary tumor type, number of involved vertebrae, interval from cancer diagnosis to RT, pre-RT ambulatory status, and time developing motor deficits. Results The 6-month survival rates for the involvement of 0, 1, 2, 3, and ≥4 extraspinal organs were 88%, 55%, 30%, 13%, and 12%, respectively (P < 0.001). In the multivariate analysis, number of involved extraspinal organs maintained significance (risk ratio 1.61; 95%-confidence interval 1.47-1.77; P < 0.001). On multivariate analysis, gender (P = 0.017), ECOG-PS (P < 0.001), primary tumor type (P < 0.001), interval from cancer diagnosis to RT (P < 0.001), pre-RT ambulatory status (P < 0.001), and time developing motor deficits (P < 0.001) were also independent predictors for survival. Conclusions The number of involved extraspinal organs is a new and independent prognostic factor in patients with MSCC and should be considered in future clinical trials.

Original languageEnglish (US)
Pages (from-to)12-15
Number of pages4
JournalClinical Neurology and Neurosurgery
Volume118
DOIs
StatePublished - Mar 2014

Fingerprint

Spinal Cord Compression
Radiotherapy
Neoplasms
Multivariate Analysis
Tissue Survival
Spine
Survival Rate
Odds Ratio
Clinical Trials
Confidence Intervals
Survival

Keywords

  • Involved extraspinal organs
  • Metastatic spinal cord compression
  • Prognostic value
  • Radiotherapy
  • Survival

ASJC Scopus subject areas

  • Clinical Neurology
  • Surgery

Cite this

Prognostic role of the number of involved extraspinal organs in patients with metastatic spinal cord compression. / Rades, Dirk; Weber, Axel; Karstens, Johann H.; Schild, Steven E.; Bartscht, Tobias.

In: Clinical Neurology and Neurosurgery, Vol. 118, 03.2014, p. 12-15.

Research output: Contribution to journalArticle

Rades, Dirk ; Weber, Axel ; Karstens, Johann H. ; Schild, Steven E. ; Bartscht, Tobias. / Prognostic role of the number of involved extraspinal organs in patients with metastatic spinal cord compression. In: Clinical Neurology and Neurosurgery. 2014 ; Vol. 118. pp. 12-15.
@article{da74ab1c83f04106b5e6ce345d963030,
title = "Prognostic role of the number of involved extraspinal organs in patients with metastatic spinal cord compression",
abstract = "Objective This study was investigated the prognostic role of the number of involved extraspinal organs in the survival of patients with metastatic spinal cord compression (MSCC). Methods Data of 552 patients treated with 30 Gy in 10 fractions of radiotherapy (RT) alone for MSCC were retrospectively analyzed. In addition to the number of involved extraspinal organs, eight potential prognostic factors were investigated including age, gender, Eastern Cooperative Oncology Group performance score (ECOG-PS), primary tumor type, number of involved vertebrae, interval from cancer diagnosis to RT, pre-RT ambulatory status, and time developing motor deficits. Results The 6-month survival rates for the involvement of 0, 1, 2, 3, and ≥4 extraspinal organs were 88{\%}, 55{\%}, 30{\%}, 13{\%}, and 12{\%}, respectively (P < 0.001). In the multivariate analysis, number of involved extraspinal organs maintained significance (risk ratio 1.61; 95{\%}-confidence interval 1.47-1.77; P < 0.001). On multivariate analysis, gender (P = 0.017), ECOG-PS (P < 0.001), primary tumor type (P < 0.001), interval from cancer diagnosis to RT (P < 0.001), pre-RT ambulatory status (P < 0.001), and time developing motor deficits (P < 0.001) were also independent predictors for survival. Conclusions The number of involved extraspinal organs is a new and independent prognostic factor in patients with MSCC and should be considered in future clinical trials.",
keywords = "Involved extraspinal organs, Metastatic spinal cord compression, Prognostic value, Radiotherapy, Survival",
author = "Dirk Rades and Axel Weber and Karstens, {Johann H.} and Schild, {Steven E.} and Tobias Bartscht",
year = "2014",
month = "3",
doi = "10.1016/j.clineuro.2013.12.007",
language = "English (US)",
volume = "118",
pages = "12--15",
journal = "Clinical Neurology and Neurosurgery",
issn = "0303-8467",
publisher = "Elsevier",

}

TY - JOUR

T1 - Prognostic role of the number of involved extraspinal organs in patients with metastatic spinal cord compression

AU - Rades, Dirk

AU - Weber, Axel

AU - Karstens, Johann H.

AU - Schild, Steven E.

AU - Bartscht, Tobias

PY - 2014/3

Y1 - 2014/3

N2 - Objective This study was investigated the prognostic role of the number of involved extraspinal organs in the survival of patients with metastatic spinal cord compression (MSCC). Methods Data of 552 patients treated with 30 Gy in 10 fractions of radiotherapy (RT) alone for MSCC were retrospectively analyzed. In addition to the number of involved extraspinal organs, eight potential prognostic factors were investigated including age, gender, Eastern Cooperative Oncology Group performance score (ECOG-PS), primary tumor type, number of involved vertebrae, interval from cancer diagnosis to RT, pre-RT ambulatory status, and time developing motor deficits. Results The 6-month survival rates for the involvement of 0, 1, 2, 3, and ≥4 extraspinal organs were 88%, 55%, 30%, 13%, and 12%, respectively (P < 0.001). In the multivariate analysis, number of involved extraspinal organs maintained significance (risk ratio 1.61; 95%-confidence interval 1.47-1.77; P < 0.001). On multivariate analysis, gender (P = 0.017), ECOG-PS (P < 0.001), primary tumor type (P < 0.001), interval from cancer diagnosis to RT (P < 0.001), pre-RT ambulatory status (P < 0.001), and time developing motor deficits (P < 0.001) were also independent predictors for survival. Conclusions The number of involved extraspinal organs is a new and independent prognostic factor in patients with MSCC and should be considered in future clinical trials.

AB - Objective This study was investigated the prognostic role of the number of involved extraspinal organs in the survival of patients with metastatic spinal cord compression (MSCC). Methods Data of 552 patients treated with 30 Gy in 10 fractions of radiotherapy (RT) alone for MSCC were retrospectively analyzed. In addition to the number of involved extraspinal organs, eight potential prognostic factors were investigated including age, gender, Eastern Cooperative Oncology Group performance score (ECOG-PS), primary tumor type, number of involved vertebrae, interval from cancer diagnosis to RT, pre-RT ambulatory status, and time developing motor deficits. Results The 6-month survival rates for the involvement of 0, 1, 2, 3, and ≥4 extraspinal organs were 88%, 55%, 30%, 13%, and 12%, respectively (P < 0.001). In the multivariate analysis, number of involved extraspinal organs maintained significance (risk ratio 1.61; 95%-confidence interval 1.47-1.77; P < 0.001). On multivariate analysis, gender (P = 0.017), ECOG-PS (P < 0.001), primary tumor type (P < 0.001), interval from cancer diagnosis to RT (P < 0.001), pre-RT ambulatory status (P < 0.001), and time developing motor deficits (P < 0.001) were also independent predictors for survival. Conclusions The number of involved extraspinal organs is a new and independent prognostic factor in patients with MSCC and should be considered in future clinical trials.

KW - Involved extraspinal organs

KW - Metastatic spinal cord compression

KW - Prognostic value

KW - Radiotherapy

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=84892506765&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892506765&partnerID=8YFLogxK

U2 - 10.1016/j.clineuro.2013.12.007

DO - 10.1016/j.clineuro.2013.12.007

M3 - Article

C2 - 24529222

AN - SCOPUS:84892506765

VL - 118

SP - 12

EP - 15

JO - Clinical Neurology and Neurosurgery

JF - Clinical Neurology and Neurosurgery

SN - 0303-8467

ER -